Related to T2cure’s Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification

• hESCs May Serve As a Colon Cancer Vaccine
  
• Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication
  
• Boehringer Ingelheim Receives EC Clearance for Once-Daily Version of Parkinson's Therapy
  
• Clemson University Obtains $9.3M for Tissue Regeneration Center
  
• Induced Pluripotent Stem Cell Technology Used to Generate Hepatocytes from Skin Cells
  
• Johns Hopkins Gets $3.7M Two-Year Grant from NIH to Study ALS
  
• Evotec Earns Roughly $3.75M as Seventh Milestone Fee from Boehringer Ingelheim
  
• Researchers Create iPSCs from Somatic Cells without Exogenous Transcription Factors
  
• EU Speeds Approval of Novartis’ mAb for CAPS in Adults and Children
  
• Researchers Elucidate How Bone Marrow Derived Stem Cells Can Be Used in Acute Lung Injury
  
• Germany Sanctions Novartis’ Cell Culture-Based H1N1 Flu Vaccine
  
• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug
  
• TiGenix Seals $23.8M Share-Based Deal to Buy Orthomimetics
  
• PGxHealth Introduces Molecular Diagnostic for Dilated Cardiomyopathy
  
• Researchers Generate Fully Functional Epidermis from hESC-Derived Keratinocytes
  
• Intercytex Wind-Down Continues with Sale of Stem Cell Therapies Assets to Pfizer for $750,000
  
• Researchers Discover Potential Mechanism for Preventing Cell Death After Stroke
  
• EU Sanctions Novartis’ Once-Daily Inhaled Therapy for COPD
  
• Proven Diagnostics to Provide Cardiovascular Tests from Berkeley HeartLab